← All trials
NCT05648669
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 4, 2022
- Primary completion
- Jul 31, 2023
- Completion date
- Feb 29, 2024
- First posted
- Dec 13, 2022
- Last posted
- Dec 13, 2022
- Enrollment
- 336
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Qilu Pharmaceutical Co., Ltd.Lead sponsor
- Chinese Academy of Medical SciencesOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.